Galapagos collaborates with Charley's Fund, Nash Avery Foundation to
develop SARM candidate drug for
(Thomson Reuters ONE) - * Second indication for Galapagos candidate drug G100192 * Sponsored by Charley's Fund and Nash Avery Foundation * Initiation of preclinical developmentMechelen, Belgium and Great Barrington, Massachusetts, USA; 17September 2009 - Galapagos NV (Euronext: GLPG), Charley's Fund Inc.and the Nash Avery Foundation announced today that they willcollaborate to investigate the potential effectiveness of Galapagos'SARM candidate drug, G100192, in treating Duchenne musculardystrophy. G100192 is an orally-available small moleculetherapeutic, which has demonstrated successful Proof of Concept inpre-clinical studies for cachexia (the loss of weight and musclemass).Charley's Fund and the Nash Avery Foundation will support the costsof pre-clinical studies to assess the potential effectiveness ofG100192 in treating Duchenne muscular dystrophy. While investigatingthis new indication, Galapagos will continue to develop the SARMtherapeutic for cachexia, and plans to initiate a Phase I clinicaltrial in healthy volunteers in the beginning of 2010."Working with Charley's Fund, the Nash Avery Foundation and expertsin the field of Duchenne gives us the opportunity to explore a secondindication for G100192 and expand the potential therapeutic benefitof this candidate drug," said Onno van de Stolpe, CEO of Galapagos."The SARM therapeutic that Galapagos is developing for cachexia couldbe of potential benefit in treating Duchenne muscular dystrophy,"said Benjamin Seckler, M.D., President of Charley's Fund. "If thepre-clinical models show efficacy in treating this disease, G100192could become one of the first small molecule candidate drugs forDuchenne - complementing the gene therapy and biologic approaches indevelopment."About Duchenne muscular dystrophyDuchenne muscular dystrophy is the most common fatal genetic disorderto affect children around the world. Approximately one in every3,500 boys worldwide is afflicted with Duchenne muscular dystrophywith 20,000 new cases reported each year. It is a devastating andincurable muscle-wasting disease associated with specific inbornerrors in the gene that codes for dystrophin, a protein that plays akey structural role in muscle fiber function. Symptoms usuallyappear in male children before age six. Progressive muscle weaknessof the legs and pelvis eventually spreads to the arms, neck, andother areas. By age 10, braces may be required for walking, and mostpatients are confined to a wheelchair by age 12. Eventually, thisprogresses to complete paralysis and increasing difficulty inbreathing. The condition is terminal and death usually occurs beforethe age of 30. The outpatient cost of care for a non-ambulatoryDuchenne muscular dystrophy patient is among the highest of anydisease. There is currently no cure for Duchenne muscular dystrophy,but for the first time in decades, there are promising therapies inor moving into development.About Charley's FundCharley's Fund Inc. is a not-for-profit foundation that financestherapeutics development for Duchenne muscular dystrophy. Thefoundation's mission is to expedite a treatment or cure in time tohelp this generation of children who suffer from Duchenne musculardystrophy. Charley's Fund Inc. targets translational research -research that moves science from the lab into human clinical trials.The 501 (c)(3) public charity was co-founded in 2004 by BenjaminSeckler, M.D. and Tracy Kramer Seckler, whose son Charley hasDuchenne muscular dystrophy. More info at: www.charleysfund.org.About Nash Avery FoundationThe Nash Avery Foundation is a not-for-profit private foundation thatis focused on financially supporting programs that will slow andeventually stop Duchenne muscular dystrophy. Nash Avery Foundationwas founded by Angela and Tom Wicka after their son Nash wasdiagnosed with DMD. The Foundation believes that the solution instopping this disease will come from a combination of well fundedscience and getting talented people focused on this disease. Moreinfo at: www.nashaveryfoundation.org.About GalapagosGalapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery anddevelopment company with small molecule programs in bone and jointdiseases, bone metastasis, cachexia, anti-infectives and metabolicdiseases. It has established risk sharing alliances with GSK,Janssen Pharmaceutica, Eli Lilly and Merck and Co. Through analliance with MorphoSys, Galapagos is also developing new antibodytherapies in bone and joint diseases. Its division BioFocus DPIoffers a full suite of target-to-drug discovery products and servicesto pharmaceutical and biotech companies and to patient foundations,encompassing target discovery and validation, screening and drugdiscovery through to delivery of pre-clinical candidates. Galapagoscurrently employs 495 people and operates facilities in sixcountries, with global headquarters in Mechelen, Belgium. More infoat: www.glpg.com.CONTACTSGalapagos NVOnno van de Stolpe, CEOTel: +31 6 2909 8028ir(at)glpg.comCharley's Fund Inc.Benjamin D. Seckler, M.D., PresidentTel: +1 413 528 5744 or +1 877 436 3363 (877-4-END-DMD)info(at)charleysfund.orgNash Avery FoundationTom C. Wicka, President and Foundertom.wicka(at)iwco.comThis release may contain forward-looking statements, including,without limitation, statements containing the words "believes,""anticipates," "expects," "intends," "plans," "seeks," "estimates,""may," "will," "could," "stands to," and "continues," as well assimilar expressions. Such forward-looking statements may involveknown and unknown risks, uncertainties and other factors which mightcause the actual results, financial condition, performance orachievements of Galapagos, or industry results, to be materiallydifferent from any historic or future results, financial conditions,performance or achievements expressed or implied by suchforward-looking statements. Given these uncertainties, the reader isadvised not to place any undue reliance on such forward-lookingstatements. These forward-looking statements speak only as of thedate of publication of this document. Galapagos expressly disclaimsany obligation to update any such forward-looking statements in thisdocument to reflect any change in its expectations with regardthereto or any change in events, conditions or circumstances on whichany such statement is based, unless required by law or regulation.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 17.09.2009 - 07:30 Uhr
Sprache: Deutsch
News-ID 5890
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 487 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos collaborates with Charley's Fund, Nash Avery Foundation to
develop SARM candidate drug for"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
